 | Notable Thursday Option Activity: GILD, GEO, TTWO
www.nasdaq.com - November 14 at 3:58 PM |
| Gilead Sciences (GILD) Shares Cross 4% Yield Mark
www.nasdaq.com - November 14 at 3:58 PM |
 | Zacks: Analysts Anticipate Gilead Sciences, Inc. (NASDAQ:GILD) Will Announce Quarterly Sales of $5.74 Billion
www.americanbankingnews.com - November 14 at 4:25 AM |
| $1.70 Earnings Per Share Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter
www.americanbankingnews.com - November 12 at 8:02 PM |
| Gilead Sciences (NASDAQ:GILD) Receives New Coverage from Analysts at SunTrust Banks
www.americanbankingnews.com - November 12 at 9:07 AM |
| Will Its HIV Lineup Save Gilead Sciences?
www.nasdaq.com - November 11 at 1:18 PM |
 | Did You Invest in Gilead Sciences?
finance.yahoo.com - November 8 at 9:20 PM |
| Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
finance.yahoo.com - November 8 at 4:19 PM |
| Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
finance.yahoo.com - November 8 at 4:19 PM |
| Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019
finance.yahoo.com - November 8 at 4:19 PM |
 | Is The Future Finally Looking Up For Gilead Sciences?
www.fool.com - November 8 at 7:52 AM |
| Brett A. Pletcher Sells 2,095 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock
www.americanbankingnews.com - November 7 at 10:44 PM |
 | Trump administration sues Gilead Sciences over HIV prevention patents
www.marketwatch.com - November 7 at 4:43 PM |
| US sues Gilead over HIV patent infringements
finance.yahoo.com - November 7 at 4:43 PM |
| Trump administration sues Gilead Sciences over HIV prevention patents
finance.yahoo.com - November 7 at 4:43 PM |
| Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 7 at 10:51 AM |
| Galapagos increases share capital through warrant exercise by Gilead
www.marketwatch.com - November 6 at 5:30 PM |
 | Gilead HIV meds show sustained benefit in late-stage studies
seekingalpha.com - November 6 at 12:29 PM |
| Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019
finance.yahoo.com - November 6 at 12:29 PM |
 | Gilead Presents 96-week Discover Trial Data...
www.benzinga.com - November 6 at 7:29 AM |
| Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
finance.yahoo.com - November 6 at 7:29 AM |
| Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®
finance.yahoo.com - November 6 at 7:29 AM |
| Gilead Sciences, Inc. (NASDAQ:GILD) EVP Sells $258,080.00 in Stock
www.americanbankingnews.com - November 5 at 8:52 PM |
| This Insider Has Just Sold Shares In Gilead Sciences, Inc. (NASDAQ:GILD)
finance.yahoo.com - November 2 at 2:06 PM |
| Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%
www.marketwatch.com - November 1 at 11:15 PM |
| Gilead to up stake in Galapagos to 25.1%
seekingalpha.com - November 1 at 11:15 PM |
| Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
finance.yahoo.com - October 31 at 6:59 PM |
| Gilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher Sells 5,677 Shares
www.americanbankingnews.com - October 30 at 10:17 PM |
| Merck strikes out in bid to reverse adverse ruling in Hep C patent fight with Gilead
seekingalpha.com - October 30 at 12:27 PM |
| UPDATE 1-Merck loses bid to revive $2.54 bln patent verdict against Gilead
finance.yahoo.com - October 30 at 12:27 PM |
| Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
finance.yahoo.com - October 30 at 12:27 PM |
| Galapagos' Quarterly Results: Gilead Profit Recognition And Important Catalysts For 2020
seekingalpha.com - October 30 at 12:37 AM |
| Can New Drugs Help Gilead Sciences Rebound?
www.fool.com - October 29 at 10:22 AM |
| Gilead Sciences (NASDAQ:GILD) Given a $76.00 Price Target by Robert W. Baird Analysts
www.americanbankingnews.com - October 28 at 7:21 PM |
| Gilead Sciences (NASDAQ:GILD) Given a $75.00 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - October 28 at 7:21 PM |
| Wells Fargo & Co Analysts Give Gilead Sciences (NASDAQ:GILD) a $81.00 Price Target
www.americanbankingnews.com - October 28 at 6:05 PM |
| Gilead Sciences (NASDAQ:GILD) PT Set at $86.00 by Guggenheim
www.americanbankingnews.com - October 28 at 4:45 PM |
| Gilead teams up with Glympse Bio in NASH program
seekingalpha.com - October 28 at 12:30 PM |
| Don't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read This
finance.yahoo.com - October 28 at 12:30 PM |
| Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
finance.yahoo.com - October 28 at 12:30 PM |
| Don't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read This
finance.yahoo.com - October 28 at 12:30 PM |
| Gilead Sciences: Soft, Yet Solid Enough
seekingalpha.com - October 27 at 11:50 PM |
| Analysts Are Getting Impatient With Gilead Despite Decent Earnings
www.nasdaq.com - October 27 at 8:49 AM |
| BMO Capital Markets Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $81.00
www.americanbankingnews.com - October 26 at 9:25 AM |
| Gilead Sciences (NASDAQ:GILD) Given New $81.00 Price Target at Raymond James
www.americanbankingnews.com - October 26 at 9:25 AM |
| Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
finance.yahoo.com - October 25 at 5:01 PM |
| Gilead Sciences' Turnaround Is Here
seekingalpha.com - October 25 at 5:01 PM |
| Gilead Sciences Q3 Revenue Is Flat, and R&D Hits Earnings
www.fool.com - October 25 at 3:14 PM |
| Gilead Sciences (NASDAQ:GILD) Given New $80.00 Price Target at Oppenheimer
www.americanbankingnews.com - October 25 at 2:41 PM |
| Gilead Sciences (NASDAQ:GILD) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - October 25 at 1:05 PM |
